Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO).


Journal

HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 22 04 2020
accepted: 24 07 2020
entrez: 16 10 2020
pubmed: 17 10 2020
medline: 17 10 2020
Statut: epublish

Résumé

As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO-CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.

Identifiants

pubmed: 33062946
doi: 10.1097/HS9.0000000000000473
pii: HemaSphere-2020-0116
pmc: PMC7523785
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e473

Informations de copyright

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

Références

Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
Eur J Haematol. 2015 Aug;95(2):160-7
pubmed: 25359318
Lancet Haematol. 2018 Feb;5(2):e82-e94
pubmed: 29275118
N Engl J Med. 1988 Oct 6;319(14):902-7
pubmed: 2901668
Haematologica. 2011 May;96(5):752-61
pubmed: 21242190
Blood. 2018 Jun 21;131(25):2761-2772
pubmed: 29692342
Leukemia. 2011 Mar;25(3):473-8
pubmed: 21127498
Blood. 1999 Sep 15;94(6):1848-54
pubmed: 10477713
N Engl J Med. 2018 Dec 27;379(26):2517-2528
pubmed: 30501481
N Engl J Med. 2009 Feb 12;360(7):659-67
pubmed: 19213679
Blood. 2014 May 22;123(21):3247-54
pubmed: 24652989
J Clin Oncol. 2006 May 20;24(15):2343-51
pubmed: 16710033
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Blood. 2019 Aug 15;134(7):641-644
pubmed: 31243043
Am J Hematol. 2015 Mar;90(3):204-7
pubmed: 25428829
Blood. 2017 Jun 22;129(25):3362-3370
pubmed: 28473407
Haematologica. 2019 Dec 26;105(11):2598-2607
pubmed: 33131249
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Leukemia. 2020 Mar;34(3):787-798
pubmed: 31628428
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Lancet Oncol. 2019 Jan;20(1):43-56
pubmed: 30522969
Blood. 2010 Nov 25;116(22):4588-90
pubmed: 20739656
Blood. 2019 Mar 14;133(11):1205-1216
pubmed: 30602617
Cancer. 1981 Jul 1;48(1):198-206
pubmed: 7237385
Lancet Oncol. 2018 Jan;19(1):65-75
pubmed: 29246803
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
N Engl J Med. 2019 Jun 06;380(23):2225-2236
pubmed: 31166681
Blood. 2019 May 9;133(19):2031-2042
pubmed: 30842083
Blood. 2019 Sep 19;134(12):960-969
pubmed: 31395603
Haematologica. 2018 Apr;103(4):698-706
pubmed: 29419437
Blood. 2014 Mar 13;123(11):1647-57
pubmed: 24421328
Blood. 2015 Jan 29;125(5):856-9
pubmed: 25634617
Lancet Oncol. 2016 Oct;17(10):1409-1418
pubmed: 27637985
Leukemia. 1994 Oct;8(10):1640-5
pubmed: 7523797
J Clin Oncol. 2019 Jun 1;37(16):1391-1402
pubmed: 30995176
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Am J Hematol. 2019 Jul;94(7):E183-E185
pubmed: 30945328
Haematologica. 2020 Jan 23;105(11):2675-2678
pubmed: 33131260
Leuk Lymphoma. 2016;57(6):1474-7
pubmed: 26402256
J Clin Oncol. 2010 Oct 10;28(29):4473-9
pubmed: 20697090
Clin Cancer Res. 2009 Feb 1;15(3):995-1004
pubmed: 19188171
Haematologica. 2019 Nov;104(11):2258-2264
pubmed: 30923097
Blood. 2019 Jul 11;134(2):111-122
pubmed: 31023700
N Engl J Med. 2014 Mar 20;370(12):1101-10
pubmed: 24401022
Haematologica. 2020 Jun 11;:
pubmed: 32527951
Blood. 2018 Aug 30;132(9):892-902
pubmed: 29997221
Leukemia. 2018 May;32(5):1070-1080
pubmed: 29467486
Leukemia. 2019 Apr;33(4):844-862
pubmed: 30700842
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
Hematol Transfus Cell Ther. 2020 Jul - Sep;42(3):269-274
pubmed: 31784406
J Clin Oncol. 2019 Feb 1;37(4):269-277
pubmed: 30523712
Br J Haematol. 2019 Apr;185(2):232-239
pubmed: 30706458
Blood. 2018 Apr 26;131(17):1955-1959
pubmed: 29437588
Am J Hematol. 2018 Feb;93(2):E52-E54
pubmed: 29164674

Auteurs

Anne Quinquenel (A)

Centre Hospitalier Universitaire (CHU) de Reims, Hôpital Robert Debré, Reims, France.
Université Reims Champagne-Ardenne, unité de Formation et de recherche (UFR) Médecine, Reims, France.

Thérèse Aurran-Schleinitz (T)

Institut Paoli Calmettes, Marseille, France.

Aline Clavert (A)

CHU d'Angers, Angers, France.

Florence Cymbalista (F)

Groupe des Hôpitaux Universitaires Paris Seine Saint-Denis (GHUPSSD), Assistance Publique Hôpitaux de Paris (AP-HP), Bobigny, France.
Unité Mixte de recherche (UMR) U978 INSERM, Bobigny, France.
Université Paris 13, UFR Santé Médecine Biologie Humaine (SMBH), Bobigny, France.

Caroline Dartigeas (C)

CHU de Tours, Tours, France.

Frédéric Davi (F)

Sorbonne Université, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

Sophie de Guibert (S)

CHU de Rennes, France.

Alain Delmer (A)

Centre Hospitalier Universitaire (CHU) de Reims, Hôpital Robert Debré, Reims, France.
Université Reims Champagne-Ardenne, unité de Formation et de recherche (UFR) Médecine, Reims, France.

Marie-Sarah Dilhuydy (MS)

CHU de Bordeaux, Pessac, France.

Pierre Feugier (P)

CHU Nancy, Vandoeuvre les Nancy, France.

Luc-Matthieu Fornecker (LM)

Institut de Cancerologie de Strasbourg Europe, Strasbourg, France.
INSERM S-113, Strasbourg, France.

David Ghez (D)

Institut Gustave Roussy, Villejuif, France.

Romain Guieze (R)

CHU de Clermont Ferrand, Clermont-Ferrand, France.

Kamel Laribi (K)

Centre Hospitalier du Mans, Le Mans, France.

Véronique Leblond (V)

Sorbonne Université, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

Stéphane Leprêtre (S)

Inserm U1245 and Department of Hematology, Centre Henri Becquerel and Normandie Univ UNIROUEN, Rouen, France.

Rémi Letestu (R)

Groupe des Hôpitaux Universitaires Paris Seine Saint-Denis (GHUPSSD), Assistance Publique Hôpitaux de Paris (AP-HP), Bobigny, France.
Unité Mixte de recherche (UMR) U978 INSERM, Bobigny, France.
Université Paris 13, UFR Santé Médecine Biologie Humaine (SMBH), Bobigny, France.

Vincent Lévy (V)

Groupe des Hôpitaux Universitaires Paris Seine Saint-Denis (GHUPSSD), Assistance Publique Hôpitaux de Paris (AP-HP), Bobigny, France.
Université Paris 13, UFR Santé Médecine Biologie Humaine (SMBH), Bobigny, France.

Florence Nguyen-Khac (F)

Sorbonne Université, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

Anne-Sophie Michallet (AS)

Centre Léon Bérard, Lyon, France.

Cécile Tomowiak (C)

CHU de Poitiers, Poitiers, France.

Olivier Tournilhac (O)

CHU de Clermont Ferrand, Clermont-Ferrand, France.

Loïc Ysebaert (L)

Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole, Toulouse, France.

Xavier Troussard (X)

CHU de Caen Normandie, Caen, France.

Classifications MeSH